Latest KARD news

Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification

Seeking Alpha · Sun, 13 Sep 2026 06:10:26 -0400

Kardigan targets genetic DCM, moderate CAVS, and post-hospitalization ASH with differentiated, biology-driven clinical programs. KARD holds $660.7M in liquid assets, providing roughly 2–3 years of runway to achieve key clinical readouts before further funding is needed. Upcoming 2027 data from all three lead programs will be pivotal in validating KARD's hypotheses and informing future capital allocation.

Kardigan to Present at Two September Investor Conferences

Business Wire · Wed, 02 Sep 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan will participate in two upcoming investor conferences: 2026 Cantor Global Healthcare Conference and Baird's 2026 Global Healthcare Conference.

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

Business Wire · Tue, 11 Aug 2026 07:00:00 -0400

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #CVD--Kardigan™, Inc. (Nasdaq: KARD) today reported financial results from the second quarter ended June 30, 2026, and provided recent business updates.

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire · Mon, 22 Jun 2026 17:03:00 -0400

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced the closing of its initial public offering.

U.S. IPO Weekly Recap: Another Biotech IPO Pops During The Short Holiday Week

Seeking Alpha · Sat, 20 Jun 2026 00:30:00 -0400

Three companies completed IPOs this past week, a short four-day trading week due to the Juneteenth holiday. While the SpaceX IPO may be in the rearview mirror, its trading still dominated financial headlines this week. Three IPOs are currently on the calendar for the week ahead, though smaller issuers may join throughout the week.

Kardigan rises in Nasdaq debut after upsized $400 million IPO

Reuters · Thu, 18 Jun 2026 12:49:22 -0400

Kardigan's shares rose ‌1.6% in their Nasdaq debut on ⁠Thursday, after the heart drug developer raised $400 million in ‌an ⁠upsized U.S. initial public offering.

Kardigan Announces Pricing of Upsized Initial Public Offering

Business Wire · Wed, 17 Jun 2026 20:30:00 -0400

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price of $16 per share. The gross proceeds from the offering are expected to be $400 million, before unde.

Market information is provided for research and visualization and is not investment advice.